Down-regulation Synaptic Vesicle Protein 2A in the Anterior Temporal Neocortex of Patients with Intractable Epilepsy

被引：69

作者：

Feng, Guibo ^{[1
]}

Xiao, Fei ^{[1
]}

Lu, Yang ^{[2
]}

Huang, Zuchun ^{[3
]}

Yuan, Jie ^{[1
]}

Xiao, Zheng ^{[1
]}

Xi, Zhiqin ^{[1
]}

Wang, Xuefeng ^{[1
]}

机构：

[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing 400016, Peoples R China

[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Geriatr, Chongqing 400016, Peoples R China

[3] Chongqing Med & Pharmaceut Coll, Dept Med, Chongqing, Peoples R China

来源：

JOURNAL OF MOLECULAR NEUROSCIENCE | 2009年 / 39卷 / 03期

关键词：

Epilepsy; Synaptic vesicle protein 2A (SV2A); Temporal lobe; REFRACTORY EPILEPSY; DRUG-RESISTANCE; BINDING-SITE; EXPRESSION; SV2A; LEVETIRACETAM; IDENTIFICATION; MECHANISMS; CELLS;

D O I：

10.1007/s12031-009-9288-2

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Synaptic vesicle protein 2A (SV2A) involvement has been reported in the animal models of epilepsy. The aim of this study was to investigate the expression of SV2A in human intractable epilepsy (IE) brain tissue. Using immunohistochemistry, immunofluorescence, and Western blot, we detected SV2A expression in tissue samples from the anterior temporal neocortex of 33 patients who had been surgically treated for IE. We compared these tissues with nine histologically normal anterior temporal lobe samples from controls. SV2A immunoreactive staining was 0.1651 +/- 0.0564 in patient group and 0.2347 +/- 0.0187 in the control group (p < 0.05) using immunohistochemistry, and this finding was consistently observed with Western blot analysis (0.1727 +/- 0.0471 versus 0.3976 +/- 0.0983, p < 0.05). Immunofluorescence staining showed that SV2A was mainly accumulated in neurons. Our findings demonstrate that down-regulation of SV2A is present in patients with temporal lobe epilepsy.

引用

页码：354 / 359

页数：6

共 19 条

[1] DIFFERENTIAL EXPRESSION OF SYNAPTIC VESICLE PROTEIN-2 (SV2) ISOFORMS [J].

BAJJALIEH, SM ;

FRANTZ, GD ;

WEIMANN, JM ;

MCCONNELL, SK ;

SCHELLER, RH .

JOURNAL OF NEUROSCIENCE, 1994, 14 (09) :5223-5235

[2] Seletracetam (UCB 44212) [J].

Bennett, Barbara ;

Matagne, Alain ;

Michel, Philippe ;

Leonard, Michele ;

Cornet, Miranda ;

Meeus, Marie-Anne ;

Toublanc, Nathalie .

NEUROTHERAPEUTICS, 2007, 4 (01) :117-122

[3]

BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284

[4] SV2 Renders Primed Synaptic Vesicles Competent for Ca2+-Induced Exocytosis [J].

Chang, Wen-Pin ;

Suedhof, Thomas C. .

JOURNAL OF NEUROSCIENCE, 2009, 29 (04) :883-897

[5] Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A) [J].

Crowder, KM ;

Gunther, JM ;

Jones, TA ;

Hale, BD ;

Zhang, HZ ;

Peterson, MR ;

Scheller, RH ;

Chavkin, C ;

Bajjalieh, SM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15268-15273

[6] Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein [J].

Gillard, M ;

Chatelain, P ;

Fuks, B .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 536 (1-2) :102-108

[7] SV2C is a synaptic vesicle protein with an unusually restricted localization:: Anatomy of a synaptic vesicle protein family [J].

Janz, R ;

Südhof, TC .

NEUROSCIENCE, 1999, 94 (04) :1279-1290

[8] SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release [J].

Janz, R ;

Goda, Y ;

Geppert, M ;

Missler, M ;

Südhof, TC .

NEURON, 1999, 24 (04) :1003-1016

[9] Early identification of refractory epilepsy. [J].

Kwan, P ;

Brodie, MJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (05) :314-319

[10] The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam [J].

Lynch, BA ;

Lambeng, N ;

Nocka, K ;

Kensel-Hammes, P ;

Bajjalieh, SM ;

Matagne, A ;

Fuks, B .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (26) :9861-9866

← 1 2 →